4basebio PLC (FRA:88Q)

Market Cap	171.14M
Revenue (ttm)	702.98K
Net Income (ttm)	-11.60M
Shares Out	n/a
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	356
Average Volume	213
Open	13.00
Previous Close	13.10
Day's Range	13.00 - 13.00
52-Week Range	11.80 - 20.60
Beta	n/a
RSI	52.06
Earnings Date	May 9, 2025

About 4basebio

4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 84
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 88Q

Financial Performance

In 2023, 4basebio's revenue was 506,000, an increase of 88.81% compared to the previous year's 268,000. Losses were -7.67 million, 48.8% more than in 2022.

Financial numbers in GBP